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Abstract: Therapeutic antibodies used to treat cancer are effective in patients with advanced-stage
disease. For example, antibodies that activate T-lymphocytes improve survival in many cancer
subtypes. In addition, antibody–drug conjugates effectively target cytotoxic agents that are specific
to cancer. This review discusses radiation-inducible antigens, which are stress-regulated proteins
that are over-expressed in cancer. These inducible cell surface proteins become accessible to antibody
binding during the cellular response to genotoxic stress. The lead antigens are induced in all histologic
subtypes and nearly all advanced-stage cancers, but show little to no expression in normal tissues.
Inducible antigens are exploited by using therapeutic antibodies that bind specifically to these stressregulated proteins. Antibodies that bind to the inducible antigens GRP78 and TIP1 enhance the
efficacy of radiotherapy in preclinical cancer models. The conjugation of cytotoxic drugs to the
antibodies further improves cancer response. This review focuses on the use of radiotherapy to
control the cancer-specific binding of therapeutic antibodies and antibody–drug conjugates.
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1. Introduction

Academic Editors: James A. Bonner

Examples of the therapeutic uses of antibodies to treat cancer include unconjugated
(naked) therapeutic antibodies that block the function of the target proteins such as EGFR
and PD-L1 on the surface of cancer cells [1,2]. Secondly, antibody–drug conjugates consist
of chemotherapeutic agents covalently linked to antibodies. The delivery of radiation
sensitizers specific to cancer using antibodies to radiation-inducible antigens has recently
been described [3]. The cytotoxic agents are released following endocytosis of the antibody–
drug conjugate into cancer cells [3–5]. Alternatively, radioimmunoconjugates have great
potential to achieve cytotoxicity when alpha emitters are conjugated to the antibodies.
Finally, bispecific and fusion antibodies are increasingly used in the treatment of cancer [6].
Thus, one antibody can lead to the development of several different types of cancer drugs.
One challenge in the development of therapeutic antibodies is the paucity of cancerspecific antigens. For example, cancer neoantigens contain mutations that are specific to
cancer (e.g., mutations in EGFR) [7]. Another example is over-expressed cancer antigens
such as her2/neu or CD20 [7]. Each of these examples of cancer antigens is limited to
particular cancer subtypes. Moreover, only a fraction of patients have cancer that expresses
these antigens; for example, 30% of breast cancer patients show her2/neu expression [8].
Furthermore, intra-tumoral heterogeneity can be a limitation, wherein the antigen is not
present on every cell within a tumor, or the antigen might be inaccessible to antibody
binding. Overcoming these limitations of cancer antigens can improve the therapeutic
antibody treatment of cancer.
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2. Radiation-Inducible Antigens
Ionizing radiation is capable of causing morphological and functional alterations in the
tissues [9]. Radiation oncology can play a role in developing cancer-targeted therapeutics
because of the exaggerated biological response of cancer cells to oxidative stress [10]. Simply stated, cancer is substantially more efficient at responding to oxidative stress following
ionizing radiation exposure compared with normal tissues. Cancer cells are more likely
to survive and propagate in a stressful tumor microenvironment when “stress regulated
proteins” are highly over-expressed. The first radiation-inducible proteins identified include cell adhesion molecules [11,12]. These inducible proteins are also not well suited for
antibody development because their expression is limited to microvascular endothelial
cells but not on cancer cells, and some are shed from cancer cells.
In contrast, the cancer cell response to radiation involving the ER stress response
(ERSR) is exaggerated in cancer [13]. One of the physiological responses of cancer cells to
radiation is the surface expression of some of these ERSR proteins. For example, GRP78 is
highly over-expressed in cancer cells and participates in the cancer response to ionizing
radiation [14–16]. We have found that these radiation-inducible antigens are molecular targets for therapeutic antibody development [15]. This strategy of targeting stress-regulated
proteins substantially increases the number of cancer antigens that can be targeted with
therapeutic antibodies. Since these cancer antigens are unregulated during standard-of-care
radiation therapy, this strategy will be useful for all cancers treated with radiation. With
advanced radiation technologies, cancer-specific radiation therapy allows marked elevation
of cell surface antigens in cancer compared to healthy tissues.
Discovery platforms to identify radiation-inducible cancer antigens include mass
spectrometry and the analysis of the differential expression of cancer proteins. Secondly,
gene expression profiling can be used to identify radiation-inducible genes. The greatest
limitation of these discovery platforms is that they identify all proteins and genes, and
not only proteins on the cancer cell surface. An approach with fewer limitations is the
use of molecular “bait” in a way that is analogous to fishing bait [17–19]. Peptide libraries
were used to discover antigens on the cancer cell surface. This method is referred to as
“biopanning” and involves the use of bacteriophage-displayed peptide libraries. This
strategy has allowed the discovery of dozens of radiation-inducible antigens on the surface
of cancer cells [17,20].
Once radiation-induced cancer cell surface antigens are discovered, they are next
prioritized (i.e., ranked) for antibody development. The ranking of antigens is based upon
the following criteria:
1.
2.
3.
4.
5.

Cancer-specific;
Accessible to antibody binding;
Not shed/remained tethered to cancer;
Over-expressed in many cancer subtypes;
Endocytosis of the antibody/antigen complex is not an essential criterion for prioritization of inducible antigens, but it is ideal for antibody–drug conjugates.

Radiation-inducible cell surface proteins include glucose-regulated protein 78 (GRP78),
tax-interacting protein-1 (TIP1), TATA-Box Binding Protein Associated Factor 15 (TAF15),
P-selectin, ICAM1, E-selectin, and Integrin αvβ3. GRP78 and TIP1 are the lead inducible
targets for drug development because they fulfill all criteria. Cell surface expression of
antigens can be induced by various mechanisms. P-selectin translocated to the surface
by the microtubule-dependent exocytosis of intracellular reservoirs within the vascular
endothelium [21]. Ionizing radiation induces the expression of cell adhesion molecules and
integrins through posttranslational modification and transcriptional induction [10,22–24].
ERSR plays an important role in the surface translocation of GRP78 [14–16].
3. Antibodies Targeted to Inducible Cancer Antigens
We use two strategies to select antibodies to induce cancer antigens (Figure 1). Mouse
monoclonal antibodies are produced by hybridoma technology, and a lead antibody is
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We use two strategies to select antibodies to induce cancer antigens (Figure 1). Mouse
monoclonal antibodies are produced by hybridoma technology, and a lead antibody is
selected for humanization (Figure 1A). Secondly, bacteriophage-displayed human antibody
selected for humanization (Figure 1A). Secondly, bacteriophage-displayed human antilibraries are used for biopanning (Figure 1B). Mouse monoclonal antibodies are selected
body libraries are used for biopanning (Figure 1B). Mouse monoclonal antibodies are sefrom hybridomas isolated from mice inoculated with the inducible proteins. These anlected from hybridomas isolated from mice inoculated with the inducible proteins. These
tibodies are prioritized based on cancer-specific binding and high affinity for the cancer
antibodies are prioritized based on cancer-specific binding and high affinity for the cancer
antigen. Murine antibodies have limited efficacy in humans due to a human anti-mouse
antigen. Murine antibodies have limited efficacy in humans due to a human anti-mouse
antibody (HAMA) response that accelerates antibody clearance from the body. Antibody
antibody (HAMA) response that accelerates antibody clearance from the body. Antibody
engineering techniques allow the humanization of murine antibodies to maintain target
engineering techniques allow the humanization of murine antibodies to maintain target
specificity and minimize the HAMA response. The antigen-binding region (CDR region)
specificity and minimize the HAMA response. The antigen-binding region (CDR region)
of lead murine antibodies is grafted into human IgG1. Human antibodies are also being
of lead murine antibodies is grafted into human IgG1. Human antibodies are also being
generated using hybridoma technology in transgenic mice models, HuMabMouse and
generated using hybridoma technology in transgenic mice models, HuMabMouse and
XenoMouse, where the mouse immunoglobulin (Ig) gene loci are replaced with human loci
XenoMouse,
where mouse
the mouse
immunoglobulin
(Ig) gene loci are replaced with human
within
the transgenic
genome
[25].
loci within the transgenic mouse genome [25].

Figure 1. Two commonly used strategies for therapeutic antibody generation. (A). Mouse monoclonal
Figure 1. Two commonly used strategies for therapeutic antibody generation. (A). Mouse monocloantibodies are generated by immunizing mice with the target antigen. Splenocytes are harvested from
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the target. Libraries are created by isolating RNA from peripheral blood and spleens of healthy
donors. VH and VL genes are amplified from the cDNA and cloned into phagemid vectors. Phageexpressing antibodies on their surface were produced. Multiple rounds of phage-antibody selection
are performed to isolate target-specific antibodies. Positive binders are screened by ELISA, flow
cytometry, and affinity to select the lead antibodies. Created with BioRender.com.

An alternative to hybridoma technology is a human antibody phage display. Our
antibody libraries were created from lymphocyte DNA donated from patients undergoing

of healthy donors. VH and VL genes are amplified from the cDNA and cloned into phagemid vectors. Phage-expressing antibodies on their surface were produced. Multiple rounds of phage-antibody selection are performed to isolate target-specific antibodies. Positive binders are screened by
ELISA, flow cytometry, and affinity to select the lead antibodies. Created with BioRender.com.
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An alternative to hybridoma technology is a human antibody phage display. Our
antibody libraries were created from lymphocyte DNA donated from patients undergoing
splenectomy
splenectomyororperipheral
peripheralblood
bloodlymphocytes.
lymphocytes.The
TheDNA-encoding
DNA-encodingantibodies
antibodiesare
arecloned
cloned
into
a
phagemid
vector,
and
the
antibody
variable
region
is
expressed
on
bacteriophage
into a phagemid vector, and the antibody variable region is expressed on bacteriophage
8
fiber
TheThe
resulting
antibody
library
has more
than 10
single-chain
fragfiberproteins.
proteins.
resulting
antibody
library
has more
thandistinct
108 distinct
single-chain
ments
of
the
variable
(scFv)
region
of
human
antibodies.
Biopanning
is
performed
to
select
fragments of the variable (scFv) region of human antibodies. Biopanning is performed to
antibodies
bindingbinding
to the inducible
antigens
listed above.
Cell-based
biopanning
is oftenis
select antibodies
to the inducible
antigens
listed above.
Cell-based
biopanning
utilized
to maintain
membrane
proteins
in their
conformation.
scFv antibodies
are
often utilized
to maintain
membrane
proteins
innative
their native
conformation.
scFv antibodies
then
prioritized
after
they
demonstrate
cancer-specific
binding
and
high
affinity
for
are then prioritized after they demonstrate cancer-specific binding and high affinity forthe
the
inducible
inducibleantigen.
antigen.Antibodies
Antibodiesare
arethen
thenimproved
improvedbybyaffinity
affinitymaturation
maturationand
anda areduction
reduction
ininimmunogenicity.
immunogenicity.Several
Severalphage-display-derived
phage-display-derivedantibodies
antibodieshave
havebeen
beenapproved
approvedinin
clinical
trials
[26].
Each
of
these
approaches
to
antibody
development
results
in
clinical trials [26]. Each of these approaches to antibody development results infunctional
functional
human
humanantibodies.
antibodies.

MechanismsofofAction
ActionofofCancer
CancerTherapeutic
TherapeuticAntibodies
Antibodies
4.4.Mechanisms
singletherapeutic
therapeuticantibody
antibodycan
canbebedeveloped
developedinto
intoseveral
severaldifferent
differenttherapeutic
therapeutic
AAsingle
agentsthat
that include
include antibody–drug
(RIC),
bisagents
antibody–drug conjugates
conjugates(ADC),
(ADC),radioimmunoconjugates
radioimmunoconjugates
(RIC),
pecific antibodies
(BsAbs),
fusion
antibodies,
CARCAR
T-cells,
immunotoxins,
and other
agents
bispecific
antibodies
(BsAbs),
fusion
antibodies,
T-cells,
immunotoxins,
and other
(Figure
2).
agents
(Figure
2).

Figure2.2.Various
Variousformats
formatsof
ofantibodies.
antibodies. Antibodies
Antibodies can be
various
Figure
be used
usedas
asnaked
nakedIgG
IgGororconjugated
conjugatedtoto
various
agents
such
as
drugs
(antibody–drug
conjugates
or
ADC),
radioisotopes
(radioimmunoconjuagents such as drugs (antibody–drug conjugates or ADC), radioisotopes (radioimmunoconjugates or
gates
RIC)
and(immunotoxins).
toxins (immunotoxins).
can be engineered
target
two different
antigens
RIC)or
and
toxins
IgGs canIgGs
be engineered
to target to
two
different
antigens (bispecific
(bispecific
IgG).
Single-chain
fragment
variables
(scFv)
can
be
fused
to
the
IgG
Fc
domain
to
generIgG). Single-chain fragment variables (scFv) can be fused to the IgG Fc domain to generate bivalent
ate bivalent scFv–Fc fusion antibodies. scFvs targeting two different antigens can be fused to each
scFv–Fc fusion antibodies. scFvs targeting two different antigens can be fused to each other with a
other with a linker making them a bispecific antibody. T-cells can be engineered into chimeric antilinker making them a bispecific antibody. T-cells can be engineered into chimeric antigenic receptor
genic receptor (CAR)-T cells where an scFv is expressed on their surface to target the desired anti(CAR)-T
cells
where formats
an scFvsuch
is expressed
their
targetthe
theFcdesired
Smaller
gen.
Smaller
antibody
as F(ab’)2on
and
Fabsurface
do not to
contain
region antigen.
of the IgG.
Creantibody
formats
such
as
F(ab’)2
and
Fab
do
not
contain
the
Fc
region
of
the
IgG.
Created
with
ated with BioRender.com.
BioRender.com.

Naked antibodies targeting cancer cells can cause cell death through various mechaNaked antibodies targeting cancer cells can cause cell death through various mechanisms. The best-known direct mechanism of cancer cell killing is blocking growth factor
nisms. The best-known direct mechanism of cancer cell killing is blocking growth factor
receptor signaling by antibodies. Antibody binding to receptors may block ligand bindreceptor signaling by antibodies. Antibody binding to receptors may block ligand binding,
ing, leading to downstream signaling inhibition (Figure 3). Cetuximab, an anti-epidermal
leading to downstream signaling inhibition (Figure 3). Cetuximab, an anti-epidermal
growth factor receptor (EGFR) mAb, induces apoptosis in tumor cells by blocking ligand
growth factor receptor (EGFR) mAb, induces apoptosis in tumor cells by blocking ligand
binding and receptor dimerization [27]. Antibodies targeting human epidermal growth
binding and receptor dimerization [27]. Antibodies targeting human epidermal growth
factor receptor 2 (Her2) achieve signaling perturbation by inhibiting hetero-dimerization
factor receptor 2 (Her2) achieve signaling perturbation by inhibiting hetero-dimerization
and internalization. The mechanism of action of antibodies targeting growth factor receptors is different from that of small-molecule tyrosine kinase inhibitors (TKIs). In contrast to
TKIs that specifically target activating mutations in the kinase domain, and are therefore
effective in a subset of patients, antibodies provide clinical benefit to all patients that overexpress the targeted antigen irrespective of its mutation status [28–30]. Another advantage
of antibodies over TKIs is their ability to activate immune effector cells as an additional
mechanism to cell killing [28–30]. Antibodies can also inhibit tumor angiogenesis. In-
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direct mechanisms of action of mAbs need the engagement of the host immune system.
These include complement-dependent cytotoxicity (CDC), antibody-dependent cellular
phagocytosis (ADCP), and antibody-dependent cellular cytotoxicity (ADCC) (Figure 3).
Most targeted mAbs can activate the complement system. Antibodies such as rituximab
and ofatumumab activate the complement cascade, enhancing their antitumor efficacy.
ADCP occurs when FcγRI, expressed on immune cells such as macrophages, binds to IgG1
or IgG3 mAbs that have opsonized a tumor cell. ADCP plays a vital role in destroying
circulating tumor cells following mAb therapy [31]. Antibodies act as bridges by binding
toREVIEW
antigens on the target cell surface via their Fab portions and linking the effector cells6via
Int. J. Mol. Sci. 2022, 23, x FOR PEER
of 12
their Fc portions.

Figure 3. Mechanisms of action of therapeutic antibodies. Naked antibodies can cause cell death by
Figure 3. Mechanisms of action of therapeutic antibodies. Naked antibodies can cause cell death
acting as antagonists or by activating the immune effector cells. Immunoconjugates deliver payloads
by acting as antagonists or by activating the immune effector cells. Immunoconjugates deliver
to the tumor. Bispecific antibodies and CAR crosslink tumor cells to T-cells. Created with BioRenpayloads
der.com.to the tumor. Bispecific antibodies and CAR crosslink tumor cells to T-cells. Created with
BioRender.com.

Using radioimmunoconjugates is another approach that delivers cytotoxic agents to
Similarly, ADCC is an immune mechanism where target cells become opsonized by
inducible antigens in cancer (Figure 3). Antibodies can be labeled with chelating moleantibodies, which then recruit effector cells to induce target cell death by non-phagocytic
cules, to which radionuclides can be added. Targeting RICs to radiation-inducible cancer
mechanisms [32]. NK cells are the primary effector type that mediates ADCC; however,
antigens is counterintuitive if merely conjugated to a β-emitter, as it would simply add a
other myeloid types such as monocytes, macrophages, neutrophils, eosinophils, and denlow LET internal emitter on top of low LET external irradiation. By way of contrast, condritic cells are also capable. Effector cells induce target cell death via cytotoxic granule
jugating high LET α-emitters or Auger-emitters to antibodies can specifically target very
release, Fas signaling, and the initiation of reactive oxygen species [32].
cytotoxic agents to cancer. For example, actinium-225 is an alpha emitter that releases four
Immunotoxins combine the specificity of mAbs with powerful cellular poisons derived
alpha
particles
per decay with
a 10-day
half-life
[34,35]. against
This half-life
is well-suited
for
from
plants
or microorganisms
(Figure
3). An
immunotoxin
mesothelin
was tested
antibodies
with
long
circulation
times.
We
conjugated
the
chelator
DTPA
to
anti-TIP1
anin combination with radiation. The results show that the immunotoxin combined with
tibodies
radiolabeled
them for imaging
and dosimetry
[36]. Cancer-selective
binding
either
low and
or high
doses of tumor-focused
radiation
led to superior
antitumor activity
[33].
of
these
RICs
was
accomplished.
We
also
conjugated
the
antibodies
to
actinium-225
and
Possible mechanisms that caused this effect were suggested to be enhanced tumor delivery
measured the biodistribution in mouse models of lung cancer.
Antibody–boron conjugates are another example of antibody-mediated drug delivery to cancer. One new consideration is boron–proton capture therapy (BPCT), which is
in early-stage drug development [37]. BPCT involves the interaction of an accelerated proton with 11B, resulting in the production of an excited 12C atom. This excited carbon-12
splits into an alpha particle and an excited 8Be atom, which subsequently degrades into
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of the immunotoxin or the upregulation of the surface expression of mesothelin following
radiation [33].
Using radioimmunoconjugates is another approach that delivers cytotoxic agents to
inducible antigens in cancer (Figure 3). Antibodies can be labeled with chelating molecules,
to which radionuclides can be added. Targeting RICs to radiation-inducible cancer antigens
is counterintuitive if merely conjugated to a β-emitter, as it would simply add a low LET
internal emitter on top of low LET external irradiation. By way of contrast, conjugating
high LET α-emitters or Auger-emitters to antibodies can specifically target very cytotoxic
agents to cancer. For example, actinium-225 is an alpha emitter that releases four alpha
particles per decay with a 10-day half-life [34,35]. This half-life is well-suited for antibodies
with long circulation times. We conjugated the chelator DTPA to anti-TIP1 antibodies and
radiolabeled them for imaging and dosimetry [36]. Cancer-selective binding of these RICs
was accomplished. We also conjugated the antibodies to actinium-225 and measured the
biodistribution in mouse models of lung cancer.
Antibody–boron conjugates are another example of antibody-mediated drug delivery
to cancer. One new consideration is boron–proton capture therapy (BPCT), which is in earlystage drug development [37]. BPCT involves the interaction of an accelerated proton with
11 B, resulting in the production of an excited 12 C atom. This excited carbon-12 splits into an
alpha particle and an excited 8 Be atom, which subsequently degrades into two additional
alpha particles. Thus, BPCT yields three alpha particles for each boron–proton capture. By
way of contrast, boron–neutron capture therapy (BNCT) requires a 10 B atom to capture a
neutron resulting in the production of an alpha particle and 7 Li atom. Antibodies to cancerspecific antigens can improve the bioavailability of boron conjugates and reduce normal
tissue toxicities. Currently, we are conjugating larger quantities of boron to antibodies
using dendrimers and nanoparticles. This approach will increase the amount of boron
within cancer during boron neutron/proton capture therapy [38].
Antibodies can be conjugated to the surface of nanoparticles, similarly to how drugencapsulated liposomes can deliver drugs such as an antibody–drug conjugate. In this case,
the drug does not need to be directly conjugated to the antibody, and such particles may
enhance drug delivery. Antibody-conjugated nanoparticles are reviewed in detail [39–41].
Bispecific antibodies (BsAbs) have gained more attention as a novel strategy for
antitumor immunity, since they can simultaneously bind two different antigens (Figure 3).
There are more than a hundred different BsAb formats described in the literature, but
they can be broadly classified into two types: IgG-like format and Fc-free format [42].
An emerging application of BsAbs is radionuclide delivery. Instead of direct coupling to
an antibody, a bsAb with an affinity for the tumor antigen and the radionuclide can be
incubated with the payload before injection. Pretargeted delivery could also be achieved
by first injecting the bsAb, and then injecting the payload. Pretargeting techniques to
deliver radionuclides to a tumor circumvent the prolonged exposure of healthy tissue to
the radionuclide, thus mitigating toxicity and adverse effects. This approach has been used
to successfully deliver yttrium-90 [43,44].
5. Radiosensitizing Therapeutic Antibodies
Radiation-sensitizing antibodies can improve therapeutic outcomes while minimizing
treatment-related adverse events such as lymphocyte depletion. Therapeutic antibodies can
improve cancer control while minimizing lymphopenia, which is associated with the use of
concomitant myelosuppressive chemotherapy [45,46]. The classic example of therapeutic
antibody enhancement of radiotherapy efficacy is the use of cetuximab in the treatment of
head and neck cancer [2]. Cetuximab binds specifically to the EGF receptor in squamous cell
carcinomas and improves the efficacy of radiotherapy. Preclinical studies of antibody–drug
conjugates have also been shown to improve the cytotoxic effects of radiotherapy [3–5].
Thus, therapeutic antibodies can serve as radiosensitizing drugs.
Similar to cetuximab, antibodies to the radiation-inducible proteins GRP78 and TIP1
enhance the cytotoxic effects of radiotherapy and improve survival in mouse models of
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cancer [15]. Cancer cell surface expression of these stress-regulated proteins increases their
accessibility to antibody binding during radiotherapy. We studied cancer-specific binding
using three approaches. Firstly, antibodies labeled with imaging agents allow for wholeanimal imaging using mouse models of cancer. This approach is useful when the mouse
target protein is homologous to that of the human protein, as is the case for GRP78 and
TIP1. Figure 4A shows whole-animal imaging following labeled antibody administration
to mice bearing irradiated cancers (Figure 4A) [3]. Secondly, we studied antibody binding
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW
8 of 12to
to irradiated cells from normal human tissues. Finally, we measured antibody binding
tissues from all organs (tissue cross-reactivity). Antibodies to the functional domains of
both GRP78 and TIP1 show cancer-specific binding in each of these studies.
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(C)
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ADCs deliver radiosensitizers to cancer. Radiotherapy then leads to enhanced cancer cell killing
in lung cancer and not normal cells, leading to specific binding of ADCs to cancer. ADCs deliver
without effecting normal cells.
radiosensitizers to cancer. Radiotherapy then leads to enhanced cancer cell killing without effecting
normal cells.

GRP78 is a radiation-inducible cancer cell surface protein discovered using the
phage-displayed
peptide library injected
into
circulation
[20].
Antibodies
to the
the phagefuncGRP78 is a radiation-inducible
cancer
cellthe
surface
protein
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using
tional
domain
of GRP78
induce
cancer-specific
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mouse models
human
displayed
peptide
library
injected
into the circulation
[20]. in
Antibodies
to theof
functional
cancers
[13,47].
We
studied
the
efficacy
of
anti-GRP78
antibodies
in
combination
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radomain of GRP78 induce cancer-specific cytotoxicity in mouse models of human candiotherapy.
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to
the
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disrupted
its
interaction
with
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survival
in
mouse
models
of
human
glioblastoma
and
lung
cancer
[15].
Humanbinding partners, reducing cancer cell viability and radiosensitization. This approach
ized
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in mousetargeting
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human
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Humandrug development.
TIP1 is a radiation-inducible antigen discovered by the phage display peptide library.
TIP1 expression levels correlate with worsened outcomes in human cancers [48]. TIP1 is a
scaffold protein that anchors signaling proteins to the cell membrane. TIP1 is translocated
to the cancer cell surface during the stress response to radiation, where it is accessible to
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ized anti-GRP78 antibodies targeting the functional domain of GRP78 are in preclinical
drug development.
TIP1 is a radiation-inducible antigen discovered by the phage display peptide library.
TIP1 expression levels correlate with worsened outcomes in human cancers [48]. TIP1 is a
scaffold protein that anchors signaling proteins to the cell membrane. TIP1 is translocated
to the cancer cell surface during the stress response to radiation, where it is accessible to
antibody binding [36]. We have found that antibodies to this inducible antigen enhance the
efficacy of radiotherapy. The functional domain (PDZ domain) of TIP1 binds proteins that
play an essential role in cancer cell viability and migration [48,49]. Antibodies to the PDZ
domain disrupt TIP1 interaction with binding partners, reducing cancer cell viability and
radiosensitization. Mouse models with human cancers showed improved survival when
anti-TIP1 antibodies were administered during radiotherapy.
6. Antibody–Drug Conjugates
Antibody–drug conjugates (ADCs) deliver cytotoxic drugs that are specific to cancer.
ADCs are emerging as a rapidly expanding class of therapeutic agents used for cancer
treatment. In fact, twelve different ADCs are FDA-approved to treat multiple cancer subtypes, and various ADCs are in the pipeline for clinical development [50–54]. There are
three components to ADCs: antibody, drug, and linker. Linkers are used to conjugate the
drug to the antibody. Following endocytosis, the drug dissociates from the antibody and
initiates cytotoxicity. Antibodies can be conjugated to radiation-sensitizing drugs. This
approach has been shown to enhance the efficacy of radiotherapy [3–5,55,56]. In those
studies, monomethyl auristatin E (MMAE) or emtansine (DM1) were conjugated to antiEGFR and Herceptin to achieve radiation sensitization in pre-clinical cancer models [4,56].
A pre-clinical assessment of ADC with radiotherapy was conducted in mouse models of
human pancreatic cancer. Anti-HER3-MMAE enhanced radiotherapy and improved tumor
control [55]. The efficacy of anti-EGFR antibody conjugated to two different radiation
sensitizing drugs, MMAE and DM1, achieved radiosensitization of preclinical models of
lung, head and neck, and esophageal cancers. Mouse models of human cancer showed
substantial tumor control and improved survival when ADC was combined with radiotherapy. This group also targeted HER2 on human cancers using antibody conjugates of
MMAE. This approach showed enhanced efficacy and improved survival in mouse models
of human cancer [5].
The use of ADCs as radiosensitizers has been validated by several studies. Most
notable is the phase I clinical trial evaluating the safety of ADC with radiotherapy in patients with newly diagnosed glioblastoma [57]. Anti-EGFR antibody conjugated to MMAF
(ABT414) was administered to glioblastoma patients receiving standard-of-care radiotherapy and TMZ. This agent was well tolerated in dose escalation up to 3.3 mg/kg. In our
recent publication, we found that the anti-TIP1 antibodies undergo endocytosis following
binding on the surface of cancer cells [3] (Figure 4B). We conjugated the chemotherapeutic
agent monomethyl auristatin E (MMAE) to anti-TIP1 antibodies and measured its enhancement of tumor control in preclinical models of irradiated cancer. The ADC increased MMAE
delivery to cancer, enhanced radiation-induced cytotoxicity, and improved tumor control.
Figure 4C shows a schematic representation of our proposed approach to guide the delivery
of radiation-sensitizers by targeting radiation-inducible antigens. In pancreatic ductal
adenocarcinoma (PDAC), an MMAE conjugated, anti-HER3-ADC increased response to
radiation through the inhibition of cell survival and the induction of DNA break formation
and apoptosis [55]. Another auristatin derivative, monomethyl auristatin F (MMAF), was
conjugated to an anti-HER2 antibody, and this conjugate also improved tumor control
combined with focal ionizing radiation [5]. MMAF had the advantage of decreased bystander and off-target effects compared with MMAE [5]. Thus, it is feasible to deliver
radiosensitizing drugs specifically to irradiated cancer, thereby improving bioavailability
and reducing systemic toxicities.
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7. Planned Clinical Trials
Radiation-inducible antigens for cancer drug delivery have not been explored in clinical trials. However, the efficacy and safety results of an ADC were evaluated in combination
with radiation and temozolomide in newly diagnosed glioblastoma [57]. Anti-EGFR antibody conjugated to MMAF (ABT414) was administered to glioblastoma patients receiving
standard-of-care radiotherapy and TMZ. This agent was well tolerated in dose escalation up
to 3.3 mg/kg. The first goal of our planned clinical trials is to learn the safety profile and the
pharmacokinetics of the therapeutic antibodies. Anti-TIP1 IgG will be administered to three
cohorts, including patients with metastatic cancer, those receiving palliative irradiation,
and a third cohort treated with checkpoint blockade antibodies. 89 Zr-antibody imaging
studies are well-established for evaluating antibody safety and pharmacokinetics [58]. We
will image the biodistribution of antibodies labeled with 89 Zr using PET imaging. The
long-term goals include studies of efficacy and reduction in myelosuppression in cancer
patients receiving radiotherapy with antibody therapy. Radiation-inducible antigens represent an opportunity for the radiation oncology community to participate in cancer drug
development. We welcome comments on planned clinical trials.
In summary, the radiation induction of cancer antigens markedly increases the number
of antigens well suited for therapeutic antibody development. These antibodies can be
used to deliver radiosensitizing drugs. This new clinical paradigm of using radiation
to guide drug delivery will enter clinical trials in radiation oncology patients with poorprognosis cancers.
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